HMBD 003
Alternative Names: HMBD-003Latest Information Update: 28 May 2021
Price :
$50 *
At a glance
- Originator Hummingbird Bioscience
- Class Antibodies; Antineoplastics
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 May 2021 No recent reports of development identified for research development in Cancer in Singapore (Parenteral)
- 21 Apr 2017 Early research in Cancer in Singapore (Parenteral)
- 21 Apr 2017 Hummingbird Bioscience announces intention to submit IND application for Cancer in the first quarter of 2019 (Hummingbird Bioscience pipeline, April 2017)